Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ifenprodil - Algernon Pharmaceuticals

Next Previous
Drug Profile

Ifenprodil - Algernon Pharmaceuticals

Alternative Names: NP 120

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Algernon Pharmaceuticals
  • Developer Algernon Pharmaceuticals; Dartmouth College
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsychotics; Antitussives; Antivirals; Benzyl compounds; Peripheral vasodilators; Phenols; Piperidines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Alpha adrenergic receptor antagonists; NMDA receptor antagonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cough; Idiopathic pulmonary fibrosis
  • Preclinical Neuroendocrine tumours; Small cell lung cancer
  • No development reported Acute lung injury; Crohn's disease; Influenza A virus H5N1 subtype; Pancreatic cancer; Respiration disorders; Ulcerative colitis
  • Discontinued COVID 2019 infections

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for preclinical development in Pancreatic-cancer in Canada
  • 05 Jun 2025 Pharmacodynamics data from preclinical trial in cough released by Seyltx
  • 05 Jun 2025 Seyltx plans the phase IIb SILINDA trial for Cough in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top